Xukai Luo Yating Sun Jiajia Li Qidi Jiang Lei Yuan Ting Li Mo Chen Liangqing Yao
10.3389/fimmu.2022.951422
Front Immunol
2022 Oct 6;13:951422.
hla-b44 supertype pd-l1 chemotherapy resistant immunotherapy ovarian clear cell carcinoma platinum resistance recurrence
CC BY
https://pubmed.ncbi.nlm.nih.gov/36275748/
Antineoplastic Agents, Immunological / therapeutic use Ovarian Neoplasms / drug therapy Ovarian Neoplasms / genetics
Antineoplastic Agents, Immunological / therapeutic use Ovarian Neoplasms / drug therapy Ovarian Neoplasms / genetics Case Reports Research Support, Non-U.S. Gov't Apoptosis B7-H1 Antigen / metabolism Carcinoma, Ovarian Epithelial Female HLA-B44 Antigen Humans Immune Checkpoint Inhibitors Neoplasm Recurrence, Local / drug therapy Platinum Programmed Cell Death 1 Receptor / metabolism B7-H1 Antigen Programmed Cell Death 1 Receptor HLA-B44 Antigen Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Platinum
PMC9582938
36275748
A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report
2022